文献速递类风湿关节炎

波多黎各医疗补助受益人类风湿关节炎患病率及改善病情抗风湿药配药模式

Prevalence of Rheumatoid Arthritis and Drug Dispensing Patterns Among Medicaid and Medicaid-Medicare Dually Eligible Beneficiaries in Puerto Rico.
PubMed 文献 · Arthritis Care Res (Hoboken) · 2021-01-01

本研究估计2016年波多黎各Mi Salud健康计划中医疗补助及双重资格受益人的类风湿关节炎(RA)患病率为每1000人2例,女性为每1000人3例,是男性的4.5倍。44%的受益人仅接受传统合成改善病情抗风湿药(csDMARDs),32%仅接受生物或靶向合成DMARDs(b/tsDMARDs),24%接受联合治疗。风湿科医生和多个专科联合处方的DMARD中位数最高,均为14。敏感性分析显示,将≥3次医疗索赔的RA病例限制为≥1次DMARD索赔后,估计患病率从每1000人6例变为3例。

要点

  • 波多黎各RA患病率低于美国本土,可能因病例定义更严格。
  • 风湿科医生和多种专科联合处方DMARD的中位数最高,均为14。
  • 纳入药房数据可提高RA索赔算法的有效性。

核心结论

  • 波多黎各医疗补助受益人中RA患病率低于美国本土报告,可能因病例定义更严格。
  • DMARD配药和费用模式与其他研究相似。
  • 包含药房数据的索赔算法识别RA具有更高有效性。

研究设计与样本

  • 研究估计2016年波多黎各Mi Salud健康计划中医疗补助及医疗补助-医疗保险双重资格受益人的RA患病率。
  • 描述DMARD配药和费用模式,并按提供者专科分层。
  • 进行敏感性分析评估RA病例定义对估计患病率的影响。

主要发现

  • 2016年RA估计患病率为每1000名受益人2例,女性为每1000人3例,是男性的4.5倍。
  • 44%的受益人仅接受csDMARDs,32%仅接受b/tsDMARDs,24%接受csDMARDs和b/tsDMARDs联合治疗。
  • 风湿科医生和多个专科联合处方的DMARD中位数最高,均为14。
  • 敏感性分析显示,将≥3次医疗索赔的RA病例限制为≥1次DMARD索赔后,估计患病率从每1000人6例变为3例。

关键数值与推荐

  • RA估计患病率:每1000名受益人2例(女性每1000人3例,男性为女性的1/4.5)。
  • DMARD配药分布:仅csDMARDs 44%,仅b/tsDMARDs 32%,联合治疗24%。
  • 风湿科医生和多个专科联合处方的DMARD中位数均为14。
  • 敏感性分析中,限制DMARD索赔后患病率从每1000人6例变为3例。

临床怎么用

  • 在RA患病率估计和病例识别中,应考虑病例定义严格程度对结果的影响。
  • 纳入药房数据可提高RA索赔算法的有效性。
  • DMARD处方模式显示风湿科医生和联合专科在DMARD管理中起重要作用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To estimate the prevalence of rheumatoid arthritis (RA) in Puerto Rico, to describe disease-modifying antirheumatic drug (DMARD) dispensing patterns by prescriber specialty, and to illustrate the impact of RA case definition on the estimated prevalence. METHODS: This study estimated the prevalence of RA in Puerto Rico during 2016 among Medicaid and Medicaid-Medicare dually eligible beneficiaries of the Mi Salud health care plan, a federally funded health insurance program. DMARD dispensing and cost patterns were described and stratified by provider specialty. A sensitivity analysis was conducted to evaluate the effect of RA case definition on estimated prevalence. RESULTS: The prevalence of RA in 2016 was estimated to be 2 cases per 1,000 beneficiaries, with 3 per 1,000 beneficiaries among females, 4.5 times that of males. In total, 44% of beneficiaries received conventional synthetic DMARDs (csDMARDs) only, 32% received biologic or targeted synthetic DMARDs (b/tsDMARDs) only, and 24% received a combination of csDMARDs and b/tsDMARDs. Rheumatologists and a combination of specialties accounted for the highest median number of dispensed DMARDs, with 14 each. A sensitivity analysis revealed that when RA cases with ≥3 medical claims were restricted to having ≥1 DMARD claim, the estimated prevalence changed from 6 to 3 cases per 1,000 beneficiaries. CONCLUSION: The prevalence of RA in Puerto Rico in this study is lower than reported in the mainland US, possibly due to more stringent criteria to define RA. DMARD dispensing and cost patterns are similar to those found in other studies. Claims algorithms that identify RA have higher validity when pharmacy data is included.

来源:Arthritis Care Res (Hoboken),查看原文。版权归原作者所有。

引用

  1. Hernández-Muñoz JJ, Wei W, Sierra-Zorita R, et al. Prevalence of Rheumatoid Arthritis and Drug Dispensing Patterns Among Medicaid and Medicaid-Medicare Dually Eligible Beneficiaries in Puerto Rico. Arthritis Care Res (Hoboken). 2021. PMID: 32475025. doi:10.1002/acr.24330

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。